<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will present at Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-17, 2022. Dr. Tian is scheduled to present on Thursday, March 17, at 12:40 p.m. Eastern Time. Interested parties
...read full article on Business Wire